The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
机构:[1]Department of Urology, West China Hospital, Sichuan University, Chengdu.四川大学华西医院[2]Institute of Urology, West China Hospital, Sichuan University, Chengdu.四川大学华西医院[3]Department of Pathology, West China Hospital, Sichuan University, Chengdu 610041, P.R. China.四川大学华西医院
Natural Science Foundation of China (NSFC 81672547); Science and
Technology Support Program of Sichuan Province (2015SZ0230-3)
and 1.3.5 project for disciplines of excellence, West China Hospital,
Sichuan University.
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2020]版:
大类|4 区医学
小类|4 区肿瘤学
最新[2023]版:
大类|4 区医学
小类|4 区肿瘤学
第一作者:
第一作者机构:[1]Department of Urology, West China Hospital, Sichuan University, Chengdu.[2]Institute of Urology, West China Hospital, Sichuan University, Chengdu.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Urology, West China Hospital, Sichuan University, Chengdu.[2]Institute of Urology, West China Hospital, Sichuan University, Chengdu.[*1]Department of Urology, Institute of Urology, West China Hospital, Sichuan University,No. 37 Guoxue Xiang, Chengdu, Sichuan 610041, P.R. China.
推荐引用方式(GB/T 7714):
Zhang Xingming,Zhang Haoran,Dai Jindong,et al.The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.[J].Japanese journal of clinical oncology.2020,50(12):1454-1463.doi:10.1093/jjco/hyaa120.
APA:
Zhang Xingming,Zhang Haoran,Dai Jindong,Liu Zhenhua,Zhu Xudong...&Shen Pengfei.(2020).The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors..Japanese journal of clinical oncology,50,(12)
MLA:
Zhang Xingming,et al."The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.".Japanese journal of clinical oncology 50..12(2020):1454-1463